國家藥監局正式批准首個四價流感疫苗上市

China's drug regulator has approved the country's first vaccine that can protect people from four influenza virus strains.
中國藥品監管機構近日批准了國內首個能夠保護人們不被4種流感病株感染的疫苗。

The four-strain vaccine adds protection against the Yamagata lineage of Influenza B, which was the main virus strain during the last flu season, according to the National Drug Administration of China.
國家藥品監督管理局稱，這種四價疫苗加入能預防上次流感季中的主要病株B乙型Yamagata流感的抗體。

Two domestic companies -- Hualan and Changsheng -- are the approved vaccine producers. The vaccine may be used on adults and children aged three years and above.
華蘭和長春兩家國內公司獲批成爲這種疫苗的生產商。該疫苗或適用於成年人及3歲以上的兒童。

H1N1 and H3N2 of Influenza A, and Victoria and Yamagata lineages of Influenza B are the common strains of human flu viruses. Until now, China had only three-strain vaccines on the market.
甲型H1N1和H3N2流感、乙型Victoria和Yamagata流感是人流感病毒的常見菌株。到目前爲止，中國市場上只有三價疫苗。

The seasonal flu is an acute respiratory infection caused by influenza viruses, affecting seniors, infants, and people with cardiopulmonary diseases in particular. Vaccination is considered the most effective way to prevent infection and guard against an epidemic.
季節性流感是由流感病毒引起的急性呼吸道傳染病，老年人、嬰兒和心肺疾病患者容易受傳染。目前，接種疫苗被認爲是預防流感和流行病最有效的方法。

Last winter, north China regions battled a surge of flu infections. Child cases reportedly rose sharply, leading to crowded hospitals.
去年冬季，華北地區出現了流感的激增。據報道，兒童病例急劇上升，導致醫院人滿爲患。